Premium
Ductal carcinoma in situ – update on risk assessment and management
Author(s) -
Pang JiaMin B,
Gorringe Kylie L,
Fox Stephen B
Publication year - 2016
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/his.12796
Subject(s) - ductal carcinoma , medicine , carcinoma in situ , carcinoma , risk assessment , oncology , breast cancer , cancer , computer science , computer security
Ductal carcinoma in situ ( DCIS ) accounts for ~20–25% of breast cancers. While DCIS is not life‐threatening, it may progress to invasive carcinoma over time, and treatment intended to prevent invasive progression may itself cause significant morbidity. Accurate risk assessment is therefore necessary to avoid over‐ or undertreatment of an individual patient. In this review we will outline the evidence for current management of DCIS , discuss approaches to DCIS risk assessment and challenges facing identification of novel DCIS biomarkers.